Brief: Neurosense Reports First Quarter 2023 Financial Results & Provides Business Update Phase 2B Als Trial Completes Enrollment, Topline Data Expected Q4 2023

Neurosense Therapeutics

01/06/2023 13:46

June 1 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS &
PROVIDES BUSINESS UPDATE: PHASE 2B ALS TRIAL COMPLETES
ENROLLMENT, TOPLINE DATA EXPECTED Q4 2023
    * NEUROSENSE THERAPEUTICS LTD - QTRLY BASIC AND DILUTED NET
LOSS
PER SHARE $0.33

Source text for Eikon:  ID:nPn8JQDpba 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))